comparemela.com

Latest Breaking News On - Gastrointestinal stromal tumor - Page 1 : comparemela.com

Bezuclastinib/Sunitinib Combination Under Evaluation in Advanced GIST

The TKI bezuclastinib plus standard-of-care sunitinib may become the new second-line standard treatment for patients with gastrointestinal stromal tumor that has progressed on imatinib.

London
City-of
United-kingdom
Houston
Texas
United-states
Robin-jones
Neeta-somaiah
Department-of-sarcoma-medical-oncology
University-of-texas-md-anderson-cancer-center
Division-of-cancer-medicine
Sarcoma-unit

Dual Inhibition With Bezuclastinib/Sunitinib Aims to Fill an Unmet Need in GIST

Combination therapy targeting multiple exons where mutations commonly develop in gastrointestinal stromal tumor may represent a promising treatment approach to increase efficacy when patients develop resistance to therapies such as imatinib.

United-kingdom
Houston
Texas
United-states
London
City-of
American
Neeta-somaiah
Robin-jones
Department-of-sarcoma-medical-oncology
American-society-of-clinical-oncology-annual-meeting
University-of-texas-md-anderson-cancer-center

Gastrointestinal Stromal Tumor Market Size in the 7MM was USD 450 million in 2022, estimates DelveInsight |

Gastrointestinal Stromal Tumor Market Size in the 7MM was USD 450 million in 2022, estimates DelveInsight |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.

Japan
Philadelphia
Pennsylvania
United-states
China
Chinese
Bristol-myers-squibb
Gleevec-imatinib-mesylate
Stivarga-regorafenib
Vitrakvi-larotrectinib
Rozlytrek-entrectinib
Gleevec-glivec-imatinib-mesylate

vimarsana © 2020. All Rights Reserved.